Withdrawn Blood Memoranda
| Title | Date Issued (year-month-day) |
Date Withdrawn (year-month-day) |
|---|---|---|
|
Reviewer Guidance for a Premarket Notification Submission For Blood Establishment Computer Software |
1997-01-13 | 2020-07-16 |
|
Draft Document Concerning the Regulation of Peripheral Blood Hematopoietic Stem Cell Products Intended for Transplantation or Further Manufacturing Into Injectable Products |
1996-02-01 | 2020-07-16 |
|
Draft Document Concerning the Regulation of Placental/Umbilical Cord Blood Stem Cell Products Intended for Transplantation or Further Manufacturing Into Injectable Products |
1995-12-01 | 2020-07-16 |
|
Recommendations for Labeling and Use of Units of Whole Blood, Blood Components, Source Plasma, Recovered Plasma or Source Leukocytes Obtained from Donors with Elevated Levels of Alanine Aminotransferase (ALT) |
1995-08-08 |
2020-07-16 |
|
Memorandum to All Registered Blood Establishments - Recommendations for the Deferral of Current and Recent Inmates of Correctional Institutions as Donors of Whole Blood, Blood Components, Source Leukocytes, and Source Plasma |
1995-06-08 |
2020-07-16 |
|
Memorandum to Registered Blood and Source Plasma Establishments, Revision of FDA Memorandum of August 27,1982: Requirements for Infrequent Plasmapheresis Donors |
1995-03-10 |
2020-07-16 |
|
Memorandum to Registered Blood Establishments, Timeframe for Licensing Irradiated Blood Products |
1995-02-03 |
2020-07-16 |
|
Memorandum to Registered Blood Establishments, Recommendations to Users of Medical Devices That Test for Infectious Disease Markers by Enzyme Immunoassay (EIA) Test Systems |
1994-12-20 |
2020-07-16 |
|
Draft Recommend-Quarantine and Disposition of Potentially HBV, HCV or HTLV-1 Contaminated Units from Prior Collections from Repeat Donors with Repeatedly Reactive Screening Tests |
1994-11-22 |
2020-07-16 |
|
Memorandum to Registered Blood Establishments - Use of an FDA Cleared or Approved Sterile Connecting Device (STCD) in Blood Bank Practices |
1994-08-05 |
2020-07-16 |
|
Recipient Serum Samples |
1994-04-06 |
2020-07-16 |
|
Software Used in Blood Establishments |
1994-03-31 |
2020-07-16 |
|
Clarification of the Use of Unlicensed Anti-HCV Supplemental Test Results in Regard to Donor Notification |
1993-08-19 |
2020-07-16 |
|
Deferral of Blood and Plasma Donors Based on Medications |
1993-07-28 |
2020-07-16 |
|
Revision of October 7, 1988 Memorandum Concerning Red Blood Cell Immunization Programs |
1992-12-16 |
2020-07-16 |
|
Nomenclature for Monoclonal Blood Grouping Reagents |
1992-09-28 |
2020-07-16 |
|
Change in Equipment for Processing Blood Donor Samples |
1992-07-21 |
2020-07-16 |
|
Inspections of Military Blood Establishments, Revised Instructions for Command Notification |
1992-06-18 |
2020-07-16 |
|
Use of Fluorognost HIV-1 Immunofluorescent Assay (IFA) |
1992-04-23 |
2020-07-16 |
|
Clarification of FDA Recommendations for Donor Deferral and Product Distribution Based on the Results of Syphilis Testing |
1991-12-12 |
2020-07-16 |
|
Disposition of Blood Products Intended for Autologous use that Test Repeatedly Reactive for Anti-HCV |
1991-09-11 |
2020-07-16 |
|
Revision to 26 October 1989 Guideline for Collection of Blood or Blood Products from Donors with Positive Tests for Infectious Disease Markers ("High Risk" Donors) |
1991-04-17 |
2020-07-16 |
|
Deficiencies Relating to the Manufacture of Blood and Blood Components |
1991-03-20 |
2020-07-16 |
|
FDA Request for Information on Blood Storage Patterns and Red Cell Contamination by Yersinia Enterocolitica |
1991-03-15 |
2020-07-16 |
|
Use of Genetic Systems HIV-2 EIA |
1990-06-21 |
2020-07-16 |
|
Autologous Blood Collection and Processing Procedures |
1990-02-12 |
2020-07-16 |
|
Eight-Hour Hold; Blood and Plasma Inspectors |
1989-11-13 |
2020-07-16 |
|
Abbott Laboratories' HIVAG-1 test for HIV-1 antigen(s) not recommended for use as a donor screen |
1989-10-04 |
2020-07-16 |
|
Requirements for Computerization of Blood Establishments |
1989-09-08 |
2020-07-16 |
|
Use of the Recombigen HIV-1 Latex Agglutination (LA) Test |
1989-08-01 |
2020-07-16 |
|
Guidance for Autologous Blood and Blood Components |
1989-03-15 |
2020-07-16 |
|
Use of the Recombigen HIV-1 LA Test |
1989-02-01 |
2020-07-16 |
|
Antibody to Human T-Cell Lymphotropic Virus, Type I (HTLV-1) Release Panel 1 |
1988-10-18 |
2020-07-16 |
|
Revised Guidelines for the Collection of Platelets, Pheresis |
1988-10-07 |
2020-07-16 |
|
Criteria for Exemption of Lot Release |
1988-08-26 |
2020-07-16 |
|
Physician Substitutes (Update) |
1988-08-15 |
2020-07-16 |
|
Discontinuance of Pre-Licensing Inspection for Immunization Using Licensed Tetanus Toxoid and Hepatitis B and Rabies Vaccines |
1988-07-07 |
2020-07-16 |
|
Recommendations for Implementation of Computerization in Blood Establishments |
1988-04-06 |
2020-07-16 |
|
Control of Unsuitable Blood and Blood Components |
1988-04-06 |
2020-07-16 |
|
Handling of Human Blood Source Materials |
1987-12-23 |
2020-07-16 |
|
Extension of Dating Period For Storage of Red Blood Cells, Frozen |
1987-12-04 |
2020-07-16 |
|
Deferral of Donors Who Have Received Human Pituitary-Derived Growth Hormone |
1987-11-25 |
2020-07-16 |
|
Reduction of the Maximum Platelet Storage Period tp 5 Days in an Approved Container |
1986-06-02 |
2020-07-16 |
|
In Vitro Diagnostic Reagent Manufacturers - Guidance for Labeling for HTLV-III/LAV Antibody Testing |
1985-12-06 |
2020-07-16 |
|
Physician Substitutes |
1984-12-14 |
2020-07-16 |
|
Equivalent Methods for Compatibility Testing |
1984-12-14 |
2020-07-16 |
|
Deferral of Blood Donors Who Have Received the Drug Accutane (isotretinoin / Roche; 13-cis-retinoic acid) |
1984-02-28 |
2020-07-16 |
|
Collection of Human Leukocytes for Further Manufacturing (Source Leukocytes) |
1981-01-28 |
2020-07-16 |